[{"data":1,"prerenderedAt":31},["ShallowReactive",2],{"project-9756e76169f1c1cc002be88f10db24da":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"landing_hospitals":14,"tech_company_name":20,"view_count":21,"favorite_count":22,"is_favorite":23,"approval_no":24,"approval_date":20,"regulatory_level":25,"valid_until":20,"filing_date":26,"intro":27,"detail_desc":20,"target_population":28,"compliance_list":29,"process":30},"9756e76169f1c1cc002be88f10db24da","2型糖尿病的人脐带间充质生物医学新技术",[7],"糖尿病","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/cover/1778074643287-mmexport1778074598518.jpg","干细胞应用",[7],"5.98万/针起(3针/疗程)","海南医科大学第一附属医院乐城医院（慈铭博鳌国际医院）",[12],[15],{"id":16,"name":12,"level":17,"city":18,"province":19,"dept":20},"9756e76169f17c63002357ff4944e2e3","三甲","省直辖县级行政区划","海南省","",643,1,false,"乐医药监〔2025〕113 号","低风险","2025年","适应症：基于现有的联合使用至少3种降糖药(包括胰岛素在内)血糖控制不佳的2型糖尿病患者",[],[],[],1780973403235]